Albumins
Albumins belong to the group of plasma proteins. Albumins serve as transport proteins in the blood and are responsible for the colloid osmotic pressure of blood plasma. They are, for instance, used to stabilize the blood circulation volume in the event of strong bleeding.
Name
|
Marketing Authorisation Holder
|
License Number
|
License Date
|
Further Information
|
Albiomin 20%
|
Biotest Pharma GmbH
|
PEI.H.03574.01.1 |
22.06.2007 |
PharmNet.Bund
|
Albiomin 5%
|
Biotest Pharma GmbH
|
PEI.H.03575.01.1 |
22.06.2007 |
PharmNet.Bund
|
Humanalbin
|
CSL Behring GmbH
|
10531a/96 |
09.02.1999 |
PharmNet.Bund
|
Human-Albumin 20% Behring, salzarm
|
CSL Behring GmbH
|
10530a/96 |
27.01.1997 |
PharmNet.Bund
|
Albumeon
|
CSL Behring GmbH
|
PEI.H.11655.01.1 |
24.05.2013 |
PharmNet.Bund
|
Alburex 5
|
CSL Behring GmbH
|
PEI.H.11429.01.1 |
25.01.2010 |
PharmNet.Bund
|
Alburex 20
|
CSL Behring GmbH
|
PEI.H.11429.02.1 |
25.01.2010 |
PharmNet.Bund
|
Plasbumin 25
|
Grifols Deutschland GmbH
|
10537a/96 |
26.05.1999 |
PharmNet.Bund
|
Plasbumin 20
|
Grifols Deutschland GmbH
|
4962.01.00 |
06.08.1984 |
PharmNet.Bund
|
Albutein 200 g/l
|
Grifols Deutschland GmbH
|
PEI.H.12090.02.1 |
26.08.2021 |
|
Albutein 50 g/l
|
Grifols Deutschland GmbH
|
PEI.H.12090.01.1 |
26.08.2021 |
|
Humanalbumin 200 g/l Kedrion
|
KEDRION S.p.A.
|
PEI.H.02994.01.1 |
12.12.2003 |
PharmNet.Bund
|
Albunorm 25%
|
Octapharma GmbH
|
PEI.H.04333.06.1 |
20.07.2015 |
PharmNet.Bund
|
Albunorm 4%
|
Octapharma GmbH
|
PEI.H.04333.05.1 |
20.07.2015 |
PharmNet.Bund
|
Albunorm 20%
|
Octapharma GmbH
|
PEI.H.04333.02.1 |
26.03.2009 |
PharmNet.Bund
|
Albunorm 5%
|
Octapharma GmbH
|
PEI.H.04333.01.1 |
26.03.2009 |
PharmNet.Bund
|
Crealb 200g/l
|
Prothya Biosolutions Netherlands B.V.
|
PEI.H.12044.02.1 |
24.09.2020 |
PharmNet.Bund
|
HUMAN ALBUMIN 50g/l Baxalta
|
Takeda GmbH
|
PEI.H.03271.01.1 |
01.04.2006 |
PharmNet.Bund
|
HUMAN ALBUMIN 200g/l Baxalta
|
Takeda GmbH
|
PEI.H.03272.01.1 |
01.04.2006 |
PharmNet.Bund
|
HUMAN ALBUMIN 250g/l Baxalta
|
Takeda GmbH
|
PEI.H.03273.03.1 |
12.10.2023 |
|
Disclaimer
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 519 in BAnz AT 26.07.2024 B6.
Summary of Product Characteristics (SmPCs) and the Package Leaflet (PL)
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.